Matinas BioPharma Investor Presentation Deck
4
Lipid Nanocrystals (LNCS): A Clinically Validated Intracellular Delivery Platform
Ca2+ ions
Phosphatidyl-
serine bilayer
Hydrophobic drug
Phosphatidylserine
}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}
{{ {S SS
Stable, phospholipid-
calcium crystalline
nanocrystals
38
50-500 nm
Delivery of small molecules and small oligonucleotides
Successful delivery of small molecules, proteins, small
oligonucleotides (siRNA, ASOs), and vaccines
Extra-hepatic targeting
Selective uptake driven by phosphatidylserine enables delivery in
infection, inflammation, oncology
Validated Blood-Brain-Barrier penetration (MAT2203)
Oral delivery
Unique structure protects cargo in GI tract, avoids first-pass
hepatic metabolism
●
Safe & stable
Deliver high-target tissue concentrations of drug with
low plasma levels and no absorption by non-target tissues
No evidence of immunogenicity or cytotoxicity
●
●
COPYRIGHT MATINAS BIOPHARMA
2024
MATINAS
BIOPHARMAView entire presentation